Centauri Therapeutics Ltd.
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology, utilizing proprietary Alphamer® technology to harness immune mechanisms for treating life-threatening diseases. The company is dedicated to addressing the needs of vulnerable patients through innovative immune-based treatments.
Industries
Nr. of Employees
small (1-50)
Centauri Therapeutics Ltd.
Centauri Therapeutics Limited, Alderley Park, Nether Alderley, Cheshire, SK10 4TG
Patents
Products
Clinical candidate for Gram‑negative pulmonary infections (preclinical stage)
A selected bifunctional immunotherapy candidate designed to target serious Gram‑negative bacterial infections in the lung, progressed for further development toward first‑in‑human studies.
Preclinical bifunctional immunotherapy with demonstrated in vitro and in vivo activity against Gram‑negative bacteria
Preclinical programme demonstrating antibody recruitment–mediated antibacterial activity and enhanced immune activation in laboratory and animal models.
Clinical candidate for Gram‑negative pulmonary infections (preclinical stage)
A selected bifunctional immunotherapy candidate designed to target serious Gram‑negative bacterial infections in the lung, progressed for further development toward first‑in‑human studies.
Preclinical bifunctional immunotherapy with demonstrated in vitro and in vivo activity against Gram‑negative bacteria
Preclinical programme demonstrating antibody recruitment–mediated antibacterial activity and enhanced immune activation in laboratory and animal models.
Services
Engagement for investment, licensing or research partnerships to advance platform applications in infectious disease and oncology.
Engagement for investment, licensing or research partnerships to advance platform applications in infectious disease and oncology.
Expertise Areas
- Antibacterial immunotherapy development
- Modular antibody-recruiting molecule design
- Preclinical microbiology and animal infection models
- Medicinal chemistry and conjugation chemistry
Key Technologies
- Modular bifunctional immunotherapy platforms
- Antibody‑recruiting molecule methodology
- Linker conjugation chemistry
- Sugar-epitope display for endogenous antibody recruitment
News & Updates
Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections, demonstrating broad-spectrum antibacterial activity in vitro and in vivo.
Centauri announced the selection of its first clinical candidate in the ABX-01 programme, based on the Alphamer® platform, targeting serious Gram-negative bacterial infections in the lung.
Centauri received a £1M grant from the PACE-AMR funding initiative, supporting the development of its immunotherapeutic platform to combat antimicrobial resistance.
The company secured a £24m Series A investment to support its antimicrobial research and development efforts.
Centauri received a grant of up to $2.7 million from CARB-X to support the development of antibacterial candidates through to first-in-human trials.
Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections, demonstrating broad-spectrum antibacterial activity in vitro and in vivo.
Centauri announced the selection of its first clinical candidate in the ABX-01 programme, based on the Alphamer® platform, targeting serious Gram-negative bacterial infections in the lung.
Centauri received a £1M grant from the PACE-AMR funding initiative, supporting the development of its immunotherapeutic platform to combat antimicrobial resistance.
The company secured a £24m Series A investment to support its antimicrobial research and development efforts.
Centauri received a grant of up to $2.7 million from CARB-X to support the development of antibacterial candidates through to first-in-human trials.